Brief: Fusion Pharmaceuticals Doses First Patient In Phase 1/2 Study Of Advanced Solid Tumor Treatment
29/08/2022 13:50
Aug 29 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2 STUDY OF FPI-1966 IN PATIENTS WITH ADVANCED SOLID TUMORS
EXPRESSING FGFR3
Source text for Eikon: ID:nCNWClNKYa
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary